title: Glucose lowering therapeutic strategies for type 2 diabetic patients with chronic kidney disease in primary care setting in france: a cross-sectional study.
abstract: Aim. To understand glucose lowering therapeutic strategies of French general practitioners (GPs) in the management of type 2 diabetes mellitus (T2DM) patients with chronic kidney disease (CKD). Methods. A multicenter cross-sectional study was conducted from March to June 2011 among a sample of French GPs who contribute to the IMS Lifelink Disease Analyzer database. Eligible patients were those with T2DM and moderate-to-severe CKD who visited their GPs at least once during the study period. Data were collected through electronic medical records and an additional questionnaire. Results. 116 GPs included 297 patients: 86 with stage 3a (Group 1, GFR = 45-60 mL/min/1.73 m(2)) and 211 with stages 3b, 4, or 5 (Group 2, GFR < 45 mL/min/1.73 m(2)). Patients' mean age was approximately 75 years. Insulin was used in 19% of patients, and was predominant in those with severe CKD. More than two-thirds of patients were treated with glucose lowering agents which were either contraindicated or not recommended for CKD. Conclusion Physicians most commonly considered the severity of diabetes and not CKD in their therapeutic decision making, exposing patients to potential iatrogenic risks. The recent patient oriented approach and individualization of glycemic objectives according to patient profile rather than standard HbA1c would improve this situation.
authors: IMS Health France, 5-7 Place de la Pyramide, 92088 Paris La Défense, France.
authors: N
authors: N
authors: Grandfils
authors: B
authors: B
authors: Detournay
authors: C
authors: C
authors: Attali
authors: D
authors: D
authors: Joly
authors: D
authors: D
authors: Simon
authors: B
authors: B
authors: Vergès
authors: M
authors: M
authors: Toussi
authors: Y
authors: Y
authors: Briand
authors: O
authors: O
authors: Delaitre
references: Diabetologia. 2012 Jun;55(6):1577-96
references: 22526604
references: Diabetes Metab. 2011 Sep;37 Suppl 2:S1-25
references: 22108432
references: Nephrol Ther. 2012 Jun;8(3):135-40
references: 22015216
references: Clin J Am Soc Nephrol. 2010 Apr;5(4):673-82
references: 20338960
references: Diabetes Metab. 2012 Dec;38(6):558-66
references: 23036461
references: Int J Clin Pharmacol Ther. 2009 Oct;47(10):617-26
references: 19825325
references: Nephrol Dial Transplant. 2004 Dec;19(12):3098-103
references: 15507475
references: Mayo Clin Proc. 2008 Dec;83(12):1373-81
references: 19046557
references: Diabetes Care. 2012 Jan;35 Suppl 1:S11-63
references: 22187469
references: N Engl J Med. 2004 Sep 23;351(13):1296-305
references: 15385656
references: Clin Ther. 2009 Nov;31(11):2608-17
references: 20110005
references: BMC Nephrol. 2009 Jun 30;10:17
references: 19563681
references: Nephrology (Carlton). 2011 Jul;16(5):468-75
references: 21457401
references: Am J Kidney Dis. 1999 Nov;34(5):795-808
references: 10561134
references: Diabetes Care. 2011 Jun;34(6):1329-36
references: 21505211